Scientific Advisory Board

Prof. Dr. med. Hanns-Martin Lorenz

Prof. Prof. Dr. med. Hanns-Martin LorenzDr. med. Hanns-Martin Lorenz is head of the section Rheumatology at the University Hospital Heidelberg and CSO of the ACURA-Rheuma-Center in Baden-Baden. He gained deep knowledge about immunology and rheumatology during his studies as a DFG-fellow at the University of Alabama in Birmingham/USA in the section of rheumatology and clinical immunology. Afterwards he worked in the University Hospital of Erlangen-Nurnberg in the section for Hematology, Rheumatology and clinical Immunology before he became head of the section Rhematology at the University Hospital in Heidelberg. Additionally he is the vice-chairman of the DGRh (Deutschen Gesellschaft für Rheumatologie /German association for Rheumatology).


Prof. Dr. rer. nat. Stephan Urban

Prof. Dr. rer. nat. Stephan UrbanProf. Dr. rer. nat. Stephan Urban is group leader of the “Hepatitis B Research Group” in the Department of Infectious Diseases at the research institute for Molecular Virology at the University Hospital in Heidelberg since 2001. With a strong background in biochemistry and molecular biology which he gained through his years at the University of Tübingen and the Max-Planck-Institute for Biochemistry in Martinsried/Munich, he focused his research on Hepatitis B and aims to develop protein-derived entry inhibitors for the treatment of acute and chronic HBV and HDV infection. In 2009 he won the Pettenkoferpreis, of the Pettenkofer Foundation, Munich: “Neue virale Zielstrukturen”. He also received a price for his translational Infectious Disease Research of the German Center of Infectious Diseases (DZIF) in 2015. Since 2014 Stephan Urban received a full DZIF-Professorship (W3) for Translational Virology at the University of Heidelberg.


Prof. Dr. med. Olaf G. Wilhelm

Prof. Dr. med. Olaf G. WilhelmProf. Dr. med. Olaf G. Wilhelm is founder and Chief Executive Officer of Therawis Pharma GmbH and Therawis Diagnostics GmbH, Munich. He also was co-founder of Wilex Biotechnology GmbH and its Managing Director from October 1, 1997 until April 8, 2001, and has been Chief Executive Officer of WILEX AG since April 9, 2001 since the conversion of the company into a stock market corporation (Wilex AG). Prof. Wilhelm managed two company acquisitions, several international development and commercialization partnerships and listed Wilex AG on the public stock Exchange. In the year 2001, he was appointed Extraordinary Professor of Gynecology at the Technical University of Munich. From 1990 to 1997, he was employed as senior physician for Obstetrics and Gynecological Oncology at the Dept. Obstetrics & Gynecology (Frauenklinik) at the Medical School of the university hospital Klinikum rechts der Isar des Klinikums rechts der Isar) at the Technical University of Munich. While at the Technical University of Munich, Prof. Wilhelm was also a member of the Clinical Research Unit of the Frauenklinik. From 1987 to 1990, he worked as a scientist for Eli Lilly and Company, Indianapolis, Indiana/USA. Prof. Wilhelm received the Midwest Trainee Award of the American Federation for Clinical Research and has authored over 70 publications. He received his MD from the Technical University of Munich. In 2011, the Technical University of Munich awarded him the title “TUM Entrepreneur of Excellence”.